You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The funding is being provided under the NYGC's Polyethnic-1000 initiative, which was launched in 2018 to study cancer care inequities in underserved populations.
GeneCentric's RNA-based molecular profiling platform will identify relevant non-muscle invasive bladder cancer subtypes and markers for potential therapeutic options.
GeneCentric and Erasmus will aim to identify RNA-based drug response markers for existing bladder cancer treatments, as well as discover novel targeted therapies.
The firm expects to launch a 510(k)-cleared version of its Bladder EpiCheck recurrence assay early next year followed by an RUO early-stage lung cancer assay.
A Broad Institute-led team found that differences by ancestry could affect not only how cancer develops but also treatment approaches.
The platform was used to subtype patients in a Phase II trial and found that patients in the claudin-low subgroup had the best two-year progression-free survival on pembrolizumab.
The firm recently published a study describing three assays for prostate cancer and reporting their sensitivity and specificity in case-control cohort.
Kindstar has also agreed to purchase Genesis systems for use by its scientists to monitor circulating tumor cells and for single-cell research.
The British molecular diagnostics company received a CE-IVD mark for the assay, called BCA-1, in June, and launched the test in October.
The flow cytometry-based assays were developed by Menlo Park, California-based IncellDx to run on Beckman Coulter instrumentation.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.